IL-2联合CVD方案治疗晚期恶性黑色素瘤临床疗效观察  

Efficacy of IL-2 Combined with CVD Chemotherapy Regimen in the Treatment of Metastatic Malignant Melanoma

作　　者：刘华[1] 陈小飞[1] 

机构地区：[1]南京医科大学附属淮安第一人民医院肿瘤内1科,江苏淮安223001

出　　处：《肿瘤预防与治疗》2009年第4期411-413,共3页Journal of Cancer Control And Treatment

摘　　要：目的:探讨IL-2联合CVD方案(DTIC+VCR+DDP)治疗晚期恶性黑色素瘤的临床疗效和毒副反应。方法:62例患者随机分成治疗组和对照组各31例,前者采用IL-2联合CVD方案化疗(治疗组),后者采用CVD方案化疗(对照组),比较两组的疗效、毒副反应、免疫水平。结果:治疗组有效率67.8%,显著优于对照组有效率41.9%(P<0.05)。治疗组化疗骨髓抑制发生率低于对照组。IL-2免疫治疗的患者在化疗一周后免疫水平较前提高,而没有免疫治疗的对照组一周后免疫水平明显下降,两者相比较有统计学意义(P<0.05)。结论:IL-2联合CVD方案治疗晚期恶性黑色素瘤疗效较好,毒副反应可耐受。Objective ： To observe the efficacy and side effects of CVD regimen （ DTIC ＋ VCR ＋ DDP） combined with IL-2 in the treatment of metastatic malignant melanoma. Methods： Sixty-two cases were devided into IL-2 combined with CVD group and CVD group randomly. The efficacy, side effects and the level of immune system of two groups were compared according to the WHO standard. Results： The efficacy of IL-2 combined with CVD group and CVD group were 67.8% and 41.9% respectively. The difference was significant . The rate of myelosuppression of IL-2 combined with CVD group was lower than that of CVD group. Immune level of patients treated with IL-2 combined with CVD continued to increase ,while that of patients treated with pure chemotherapy dereased significantly. Conclusion： IL-2 plus CVD shows a high response rate and can be well tolerated by patients with metastatic malignant melanoma with less side effects.

关 键 词：白细胞介素-Ⅱ(IL-2) 联合化疗 晚期恶性黑色素瘤 氮烯咪胺 

分 类 号：R739.5[医药卫生—肿瘤] R730.58[医药卫生—临床医学]